Multicenter, Randomized, 2 x 2 Factorial, Phase 3 Study to Assess the Efficacy of Carvedilol and Empagliflozin on Improvement of Right Ventricular Remodeling in Patients With Severe Functional Tricuspid Regurgitation
Latest Information Update: 10 Apr 2025
At a glance
- Drugs Carvedilol (Primary) ; Empagliflozin (Primary)
- Indications Tricuspid valve insufficiency
- Focus Therapeutic Use
- Acronyms PROVE
Most Recent Events
- 19 Mar 2025 Status changed from active, no longer recruiting to completed.
- 11 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2023 Planned End Date changed from 1 May 2024 to 1 Dec 2024.